Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Therapies after progression on PD-1 inhibitor and platinum
12 evidence topics · 12 sources
Amivantamab and hyaluronidase-lpuj: indication and limitation of use
Amivantamab and hyaluronidase-lpuj: date of accelerated approval
OrigAMI-4: population and prior therapy
OrigAMI-4: efficacy results
| Outcome | RYBREVANT FASPRO (N=102) |
|---|---|
| Overall response rate (95% CI) | “42% (32%, 52%)” |
| Complete response | “15%” |
| Partial response | “28%” |
| Duration of response, range (months) | “1.4+, 19.7+” |
| Patients with duration of response of 6 months or longer | “56%” |
First approval in 10 years after prior platinum-based chemotherapy
Cetuximab monotherapy after platinum: indication and response
PD-1 inhibitors after platinum in disease not previously treated with a PD-1 inhibitor
Pembrolizumab versus methotrexate, docetaxel, or cetuximab after platinum: overall survival
Next-line therapy after first-line pembrolizumab in KEYNOTE-048
“The objective response rate on second-course pembrolizumab was 27.3% (3 of 11).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“PFS2 was similar after pembrolizumab and longer after pembrolizumab-chemotherapy on next-line taxanes and shorter after pembrolizumab and similar after pembrolizumab-chemotherapy on next-line nontaxanes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Salvage chemotherapy after anti-PD-(L)1 therapy: retrospective cohort
“Retrospective cohort analysis of 63 R/M patients treated with SCT after antiPD-(L1)-based therapy between January 2015 and August 2022.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Up to 71% received SCT as third line or beyond. ORR to SCT was 49% with higher rates in PD-L1 positive tumors, 71% vs. 18% (p=0.001), and cetuximab-containing regimens, 68% vs. 39% (p=0.026).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“OS and PFS were 9.3 months (95% CI, 6.5–12.3) and 4.1 months (95% CI, 3.0–5.8) respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cetuximab-based salvage chemotherapy after immune checkpoint inhibitors: real-world cohort
“In recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) there is no established standard therapy after progression to immune checkpoint inhibitors (ICI).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among 80 patients, 96% and 100% received cetuximab-based first and second SCAI, respectively” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“First SCAI: ORR of 59% (41/70; 31 partial and 10 complete responses)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“DoR of 9.4 months, and PFS and OS of 5.9 and 12.4 months, respectively” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“grade 3–5 AEs, 38.7% (first SCAI) and 47% (second SCAI) with no toxic deaths.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Range of response and survival with conventional salvage regimens
“Conventional salvage regimens (taxanes, methotrexate, cetuximab) yield response rates of 21–69% but with short median PFS (2.9–5.5 months) and OS (6.3–13.3 months)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As a result, there is no clear standard of care choice in second-line treatment” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote